What is Primus Pharmaceuticals?
Primus Pharmaceuticals is a specialized entity in the prescription medical nutrition market, dedicated to developing and distributing clinically validated products for chronic disease management. Their product portfolio, which includes well-known brands such as EpiCeram, Fosteum PLUS, Rheumate, Vasculera, impoyz Cream, Sernivo Spray, and Promiseb, is designed for physician-supervised use. The company upholds stringent purity and quality manufacturing standards to ensure product efficacy and patient safety. Through its Primus Care Direct program, the company also aims to improve patient access to its offerings via participating pharmacies, thereby enhancing overall patient care.
How much funding has Primus Pharmaceuticals raised?
Primus Pharmaceuticals has raised a total of $2.5M across 2 funding rounds:
Debt
$1M
Debt
$1.6M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.6M led by PPP
Key Investors in Primus Pharmaceuticals
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Primus Pharmaceuticals?
The substantial enterprise-level funding, particularly the recent major strategic investment, signals Primus Pharmaceuticals' readiness for significant scaling and market expansion. This capital infusion is likely to fuel further research and development into novel medical nutrition solutions, enhance manufacturing capabilities, and broaden the distribution network for their existing product lines. The company's focus on physician-supervised, high-purity products positions it for continued growth within the specialized healthcare segment, potentially exploring new therapeutic areas or strengthening its presence in existing ones.
See full Primus Pharmaceuticals company page
